ADA 2021: Dapagliflozin Reduces Incidence of Type 2 Diabetes in Patients With Chronic Kidney Disease
Findings are consistent with those seen in heart failure patients
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.